Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Neuroendocrine carcinoma of the skin (Merkel cell)
Trial Type:  Treatment
Trial Status:  Active
Results 1-22 of 22 for your search:
Start Over
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2586.00, NCI-2012-02779, 2586, P30CA015704, NCT01758458
DOTA-TOC in Metastasized Neuroendocrine Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MAW002, NCT00978211
Merkel Positron Emission Tomography (PET) Protocol
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TROG 09.03, ACTRN12610000480088, NCT01013779
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: EudraCT 2006-004748-22, NCT01203306
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, A021202, U10CA180821, U10CA031946, NCT01841736
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-490, NCT02036476
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PH-F16IL2TAXO-03/12, NCT02054884
Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 100070-003, 2014-000445-79, NCT02155647
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CA184-205, NCT02196961
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00848, MK-3475, CITN-09, U01CA154967, NCT02267603
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GI 195, NCT02318784
Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 38RC14.040, 2014-001273-13, NCT02351128
Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008L03278, NCT01043016
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IDC-G100-2013-001, NCT02035657
Phase Ib Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2014-012-00CH1, NCT02267967
Best Therapy for Patients With Neuroendocrine Tumors
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: ZBB-NET-1, NCT00815620
Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: 35 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: MT-DMG-1, NCT01536444
Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 2014P000121, NCT02150863
Start Over